Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2484 | Pioglitazone Wiki | 0.71 |
drug3199 | Standard of care Wiki | 0.13 |
drug2490 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D011658 | Pulmonary Fibrosis NIH | 0.18 |
D000860 | Hypoxia NIH | 0.13 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002206 | Pulmonary fibrosis HPO | 0.18 |
HP:0012418 | Hypoxemia HPO | 0.13 |
Navigate: Correlations HPO
There are 2 clinical trials
Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by - % change in forced vital capacity (FVC) - % fibrosis in high resolution computed tomography (HRCT) of the lung
Description: To investigate the effect of pirfenidone administered for 24 weeks measuring the number of patients who have pulmonary fibrotic changes from baseline after suffering severe COVID19 pneumonia, analysed by Change From Baseline in % in forced vital capacity (FVC) Change From Baseline % fibrosis in high resolution computed tomography (HRCT) of the lung
Measure: To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection Time: 24 weeksDescription: Number of patients who show maintenance of stability or functional improvement: stability will be considered when the FVC does not increase more than 10% or does not decrease more than 10% and the DLCO does not increase more than 15% or decreases more than 15%. An increase in% FVC greater than 10% or in DLCO greater than 15% will be considered significant improvement.
Measure: Maintenance of stability or functional improvement FVC Time: 24 weeksDescription: Rate of decreased oxygen requirement for physical activity in patients
Measure: Decreased oxygen requirement for physical activity Time: 24 weeksDescription: Number of patients who have improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m
Measure: Improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m Time: 24 weeksDescription: Number of Hospitalizations (general and due to respiratory problems)
Measure: Hospitalizations (general and due to respiratory problems) Time: 24 weeksDescription: Number of Visits to the Emergency or Day Hospital for respiratory causes
Measure: Visits to the Emergency or Day Hospital for respiratory causes Time: 24 weeksDescription: Number of patients who need Lung transplantation
Measure: Lung transplantation Time: 24 weeksDescription: Number of patients who die
Measure: Death Time: 24 weeksA randomized, open label, two arm, pilot trial of Pirfenidone 2,403 mg administered per nasogastric tube or orally as 801mg TID for 4 weeks in addition to Standard of Care (SoC), compared to SoC alone, in a population of COVID-19 induced severe ARDS. Patients will be randomized according to 1:1 ratio to one of the trial arms: Pirfenidone (intervention arm) or SoC (control arm).
Description: Measured in number of days
Measure: Ventilation free days to day 28 (VFD28) Time: Up to 28 days from admission to ICUDescription: Number of SAEs divided to number of patients
Measure: Severe adverse events (SAEs) rate Time: Through study completion, an average of 1 yearDescription: Includes all cause mortality, mortality in the ICU, 28 days mortality, 60 days mortality, in-hospital mortality, and ARDS related mortality. Measured in number of days.
Measure: Mortality Time: Through study completion, an average of 1 yearDescription: Measured in number of days
Measure: ICU length of stay Time: Through study completion, an average of 1 yearDescription: Part of mechanical ventilation parameters, calculated as tidal volume divided by the difference between plateau pressure and PEEP. Daily average will be assessed until extubation. Units are mL/cmH2O.
Measure: Lung compliance Time: Through study completion, an average of 1 yearDescription: Part of mechanical ventilation parameters, it is the lung volume representing the volume of air displaced between normal inhalation and exhalation. Measured continuously by the ventilator, calculated and represented as area under the curve after omitting extreme values <5 and >95 percentiles. Measured in mL.
Measure: Tidal Volume Time: Through study completion, an average of 1 yearDescription: Part of mechanical ventilation parameters, it is the pressure in the lungs above atmospheric pressure that exists at the end of expiration. It is set by the treating physicians according to the clinical situation of the patient, and will be documented daily until extubation. Measured in cmH2O.
Measure: Positive End Expiratory Pressure (PEEP) Time: Through study completion, an average of 1 yearDescription: Part of mechanical ventilation parameters, it is the difference between plateau pressure and PEEP. Measured continuously by the ventilator, calculated and represented as area under the curve after omitting extreme values <5 and >95 percentiles.
Measure: Driving Pressure Time: Through study completion, an average of 1 yearDescription: Assessed by St George Respiratory Questionnaire (SGRQ). Scoring range from 0 to 100, with higher scored indicating more limitation.
Measure: Quality of life questionnaire Time: on admission and 6 months after dischargeDescription: Part of pulmonary function tests, it is the maximum amount of air a person can expel from the lungs after a maximum inhalation. Measured on a spirometer in mL.
Measure: Vital Capacity (VC) Time: On admission (if possible) and 6 months after dischargeDescription: Part of pulmonary function tests, it is the vital capacity that results from a maximally forced expiratory effort. Measured on a spirometer in mL.
Measure: Forced Vital Capacity (FVC) Time: On admission (if possible) and 6 months after dischargeDescription: Part of pulmonary function tests, it is the volume of air exhaled at the end of the first second of forced expiration. Measured on a spirometer in mL.
Measure: Forced Expiratory Volume at first second (FEV1) Time: On admission (if possible) and 6 months after dischargeDescription: Part of pulmonary function tests, it is the extent to which oxygen passes from the air sacs of the lungs into the blood. Measured on a spirometer in mL/min/kPa.
Measure: Diffusing Capacity for Carbon Monoxide (DLCO) Time: On admission (if possible) and 6 months after dischargeDescription: The distance covered over a time of 6 minutes, measured in meters.
Measure: 6 minutes walking test Time: 6 months after discharge from hospitalAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports